Clinical and anamnestic factors of chronic migraine and drug-inducedheadache

Introduction. Migraine remains one of the most common forms of headache and is a serious medical problem that requires improved therapeutic strategies. Considering the widespreadprevalence of chronic migraine (CM), taking into account the factors influencing the outcome of treatment can help to create more personalized and, therefore, more effective therapies.

Aim. To study the clinical and anamnestic factors influencing the effectiveness of treatment of patients with CM.

Materials and methods. 54 patients aged 18 to 50 years with CM with and without drug-induced headache (LIGB) were observed. The frequency and severity of migraines were assessed every 2 months for 12 months. The survey of patients took place during each visit and included an assessment of all clinical and anamnestic data regarding headache (GB).

Results. Patients with CM did not significantly differ in clinical and anamnestic parameters from patients with XM and LIGB. The presence of LIGB in migraine is not associated with the frequency of migraine hypertension and does not change the response to therapy (p = 0.072). During treatment, there was an average decrease in the frequency of migraine headaches per month by 2 episodes (β = -2.15, p < 0.001). The initial severity of GB was associated with the number of days with non-migraine GB (β = -0.23, p = 0.003), the provoking effect of tyramine-rich foods (β = 3.91, p = 0.049), physical fatigue (β = 3.51, p = 0.047), and an increase in blood pressure in the migraine pattern (β = 4.14, p = 0.047). However, these factors did not affect the decrease in the frequency of GB and were not associated with the presence of LIGB.

Conclusion. In СM, the number of days with non-migraine GB, the presence of a provoking effect of food rich in tyramine, physical fatigue, and an increase in blood pressure in the migraine attack pattern are associated with the number of days with migraine per month, but do not affect the decrease in the frequency of GB in dynamics and LIGB.

1. Filatova EG, Osipova VV, Tabeeva GR, Parfenov VA, Ekusheva EV, Azimova YE et al. Diagnosis and treatment of migraine: Russian experts’ recommendations. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(4):4–14. (In Russ.) https://doi.org/10.14412/2074-2711-2020-4-4-14.

2. Tabeeva GR. Problems in the selection of effective analgesics for migraine. Neurology, Neuropsychiatry, Psychosomatics. 2023;15(5):109–116. (In Russ.) https://doi.org/10.14412/2074-2711-2023-5-109-116.

3. Tabeeva GR, Kosivtsova OV. Modern strategies for the treatment of migraine attacks and the possibility of a differentiated approach. Meditsinskiy Sovet. 2023;17(21):54–62. (In Russ.) https://doi.org/10.21518/ms2023-425.

4. Aguilar-Shea AL, Membrilla Md JA, Diaz-de-Teran J. Migraine review for general practice. Aten Primaria. 2022;54(2):102208. https://doi.org/10.1016/j.aprim.2021.102208.

5. Shagbazyan AE, Kovalchuk NA, Tabeeva GR. Role of educational programs in management of patients with medication-overuse headache. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(3):27–33. https://doi.org/10.14412/2074-2711-2021-3-27-33.

6. Sergeev AV, Guziy EA, Kovalchuk NA, Sokolov EA, Grigoriev GV, Tabeeva GR. Comparative analysis of the efficacy of different treatment strategies in medication overuse headache: an open-label prospective trial. Neurology, Neuropsychiatry, Psychosomatics. 2024;16(1 Suppl.):45–51. (In Russ.) https://doi.org/10.14412/2074-2711-2024-1S-45-51.

7. Tabeeva GR, Osipova VV, Filatova EG, Azimova YE, Amelin AV, Artyomenko AR et al. Evaluation and treatment of medication-overuse headache: Russian experts’ guidelines. Neurology, Neuropsychiatry, Psychosomatics. 2022;14(1):4–13. (In Russ.) https://doi.org/10.14412/2074-2711-2022-1-4-13.

8. Guziy EA, Sergeev AV, Tabeeva GR. Clinical and psychoemotional characteristics of patients with medication overuse headache. Neurology, Neuropsychiatry, Psychosomatics. 2024;16(1 Suppl.):52–58. (In Russ.) https://doi.org/10.14412/2074-2711-2024-1S-52-58.

9. Vashchenko NV, Korobkova DZ, Skorobogatykh KV, Azimova YE. Efficacy and safety of anti-CGRP(r) monoclonal antibodies in real clinical practice: preliminary analysis after three months of therapy. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(6):62–66. (In Russ.) https://doi.org/10.14412/2074-2711-2021-6-62-66.

10. Lipton RB, Buse DC, Nahas SJ, Tietjen GE, Martin VT, Löf E et al. Risk factors for migraine disease progression: a narrative review for a patient-centered approach. J Neurol. 2023;270(12):5692–5710. https://doi.org/10.1007/s00415-023-11880-2.

11. Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache. 2015;55(Suppl. 2):103–122. https://doi.org/10.1111/head.12505_2.

12. Tabeeva GR, Kosivtsova OV, Kovalchuk NA, Orlyuk TA. Refractory migraine. Neurology, Neuropsychiatry, Psychosomatics. 2024;16(2):76–86. (In Russ.) https://doi.org/10.14412/2074-2711-2024-2-76-86.

13. Golovacheva VA, Golovacheva AA, Tarshilova AR, Osipova VV. Typical clinical practice of treating patients with chronic migraine. Neurology, Neuropsychiatry, Psychosomatics. 2024;16(1 Suppl.):31–37. (In Russ.) https://doi.org/10.14412/2074-2711-2024-1S-31-37.

14. Golovacheva VA, Golovacheva AA. Addiction to analgesics in patients with chronic migraine and medication-overuse headache. Neurology, Neuropsychiatry, Psychosomatics. 2024;16(5):38–44. (In Russ.) https://doi.org/10.14412/2074-2711-2024-5-38-44.

15. Probyn K, Bowers H, Caldwell F, Mistry D, Underwood M, Matharu M, Pincus T; CHESS Team. Prognostic factors for chronic headache: A systematic review. Neurology. 2017;89(3):291–301. https://doi.org/10.1212/WNL.0000000000004112.

16. Guziy EA, Sergeev AV, Tabeeva GR. Evaluation of the efficacy of preventive therapy in chronic migraine with or without medication overuse headache: data from a prospective study. Neurology, Neuropsychiatry, Psychosomatics. 2024;16(1 Suppl.): 59–65. (In Russ.) https://doi.org/10.14412/2074-2711-2024-1S-59-65.

17. Yuan D, Zhang Y, Li Q, Lv Y, Li X, Yu Y et al. Factors Affecting Preventive Treatment Outcomes for Patients With Newly Diagnosed Chronic Migraine and Their Compliance With Treatment Recommendations in Chongqing Province, China: An Open-Label Prospective Study With Retrospective Baseline. Front Neurol. 2020;11:227. https://doi.org/10.3389/fneur.2020.00227.

18. Luconi R, Bartolini M, Taffi R, Vignini A, Mazzanti L, Provinciali L, Silvestrini M. Prognostic significance of personality profiles in patients with chronic migraine. Headache. 2007;47(8):1118–1124. https://doi.org/10.1111/j.1526-4610.2007.00807.x.